Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 100 | 2024 | 3626 | 10.710 |
Why?
|
Isocitrate Dehydrogenase | 31 | 2024 | 951 | 5.240 |
Why?
|
fms-Like Tyrosine Kinase 3 | 16 | 2024 | 494 | 3.970 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 25 | 2023 | 11878 | 1.800 |
Why?
|
Myelodysplastic Syndromes | 14 | 2024 | 1399 | 1.760 |
Why?
|
Antineoplastic Agents | 30 | 2024 | 13677 | 1.690 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 9 | 2024 | 1560 | 1.680 |
Why?
|
Glutarates | 5 | 2018 | 242 | 1.570 |
Why?
|
Cytarabine | 14 | 2023 | 695 | 1.520 |
Why?
|
Triazines | 8 | 2024 | 311 | 1.510 |
Why?
|
Mutation | 41 | 2024 | 30237 | 1.490 |
Why?
|
Glycine | 7 | 2024 | 672 | 1.440 |
Why?
|
Protein Kinase Inhibitors | 16 | 2024 | 5704 | 1.420 |
Why?
|
Hematopoietic Stem Cell Transplantation | 20 | 2023 | 5717 | 1.400 |
Why?
|
Aminopyridines | 8 | 2024 | 580 | 1.310 |
Why?
|
Azacitidine | 7 | 2023 | 336 | 1.300 |
Why?
|
Myeloproliferative Disorders | 5 | 2024 | 616 | 1.240 |
Why?
|
Enzyme Inhibitors | 11 | 2021 | 3728 | 1.230 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 3 | 2024 | 93 | 1.130 |
Why?
|
Leukocytosis | 4 | 2020 | 251 | 1.060 |
Why?
|
Azepines | 2 | 2019 | 329 | 1.050 |
Why?
|
Immunoconjugates | 4 | 2024 | 975 | 1.020 |
Why?
|
Leukemia, Myeloid | 4 | 2019 | 693 | 1.020 |
Why?
|
Pyridines | 8 | 2024 | 2894 | 0.990 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2020 | 686 | 0.970 |
Why?
|
Leukemia, Promyelocytic, Acute | 2 | 2018 | 249 | 0.920 |
Why?
|
Phenylurea Compounds | 7 | 2020 | 531 | 0.880 |
Why?
|
Bone Marrow | 8 | 2017 | 2935 | 0.840 |
Why?
|
Chromosomes, Human, Pair 17 | 2 | 2014 | 418 | 0.800 |
Why?
|
SEER Program | 6 | 2022 | 1444 | 0.790 |
Why?
|
Eosinophilia | 4 | 2020 | 556 | 0.760 |
Why?
|
Hematologic Neoplasms | 7 | 2024 | 1907 | 0.720 |
Why?
|
Myelopoiesis | 1 | 2021 | 135 | 0.690 |
Why?
|
Remission Induction | 16 | 2022 | 2410 | 0.690 |
Why?
|
Philadelphia Chromosome | 4 | 2024 | 119 | 0.670 |
Why?
|
Aniline Compounds | 2 | 2022 | 1094 | 0.660 |
Why?
|
Long QT Syndrome | 1 | 2023 | 472 | 0.620 |
Why?
|
Niacinamide | 3 | 2016 | 418 | 0.610 |
Why?
|
Hypereosinophilic Syndrome | 2 | 2021 | 97 | 0.600 |
Why?
|
Pyrimidines | 4 | 2020 | 3048 | 0.600 |
Why?
|
Humans | 159 | 2024 | 768171 | 0.590 |
Why?
|
Leukemia, Neutrophilic, Chronic | 1 | 2016 | 14 | 0.550 |
Why?
|
Aged | 73 | 2024 | 171502 | 0.550 |
Why?
|
Aged, 80 and over | 42 | 2024 | 59626 | 0.550 |
Why?
|
Receptors, Colony-Stimulating Factor | 1 | 2016 | 51 | 0.550 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 263 | 0.550 |
Why?
|
Communicable Diseases | 2 | 2017 | 873 | 0.550 |
Why?
|
Maximum Tolerated Dose | 6 | 2024 | 899 | 0.540 |
Why?
|
Proto-Oncogene Proteins c-pim-1 | 2 | 2013 | 31 | 0.500 |
Why?
|
Drug Resistance, Neoplasm | 9 | 2024 | 5341 | 0.480 |
Why?
|
Blood Cells | 2 | 2016 | 309 | 0.470 |
Why?
|
Hedgehog Proteins | 1 | 2019 | 771 | 0.470 |
Why?
|
Middle Aged | 69 | 2024 | 223487 | 0.470 |
Why?
|
Anilides | 1 | 2017 | 413 | 0.460 |
Why?
|
Recurrence | 11 | 2024 | 8509 | 0.460 |
Why?
|
Core Binding Factors | 1 | 2014 | 29 | 0.460 |
Why?
|
Sarcoma, Myeloid | 1 | 2014 | 52 | 0.460 |
Why?
|
Oncogene Proteins, Fusion | 5 | 2022 | 1613 | 0.450 |
Why?
|
Benzimidazoles | 3 | 2020 | 864 | 0.450 |
Why?
|
Edema | 2 | 2021 | 765 | 0.430 |
Why?
|
Translocation, Genetic | 3 | 2014 | 1394 | 0.430 |
Why?
|
Idarubicin | 3 | 2019 | 59 | 0.420 |
Why?
|
Aminoglycosides | 1 | 2013 | 161 | 0.410 |
Why?
|
Molecular Targeted Therapy | 3 | 2021 | 2830 | 0.400 |
Why?
|
Male | 76 | 2024 | 364731 | 0.400 |
Why?
|
Tandem Repeat Sequences | 4 | 2016 | 183 | 0.400 |
Why?
|
Female | 77 | 2024 | 397187 | 0.400 |
Why?
|
Adult | 56 | 2024 | 223646 | 0.400 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2013 | 411 | 0.390 |
Why?
|
Immunotherapy | 5 | 2022 | 4754 | 0.390 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2024 | 9419 | 0.390 |
Why?
|
Leukemia, Erythroblastic, Acute | 1 | 2012 | 176 | 0.390 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2013 | 361 | 0.390 |
Why?
|
Graft vs Host Disease | 4 | 2022 | 3049 | 0.380 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2014 | 410 | 0.380 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 2012 | 168 | 0.380 |
Why?
|
Ear, External | 1 | 2012 | 165 | 0.380 |
Why?
|
Epigenesis, Genetic | 4 | 2021 | 3833 | 0.370 |
Why?
|
Survival Rate | 14 | 2021 | 12840 | 0.370 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 230 | 0.360 |
Why?
|
Carbazoles | 2 | 2011 | 230 | 0.360 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 384 | 0.360 |
Why?
|
Neutrophil Infiltration | 1 | 2013 | 394 | 0.350 |
Why?
|
Antimetabolites, Antineoplastic | 5 | 2021 | 646 | 0.350 |
Why?
|
Ear Diseases | 1 | 2012 | 181 | 0.350 |
Why?
|
Immunologic Factors | 2 | 2018 | 1596 | 0.340 |
Why?
|
Chromosome Deletion | 1 | 2014 | 1385 | 0.330 |
Why?
|
Mastocytosis | 1 | 2011 | 150 | 0.330 |
Why?
|
Rectum | 1 | 2014 | 900 | 0.320 |
Why?
|
Disease-Free Survival | 9 | 2021 | 6847 | 0.320 |
Why?
|
Salvage Therapy | 4 | 2019 | 1273 | 0.310 |
Why?
|
Piperidines | 2 | 2013 | 1667 | 0.290 |
Why?
|
Neoplasms, Second Primary | 1 | 2015 | 1061 | 0.280 |
Why?
|
Insurance Coverage | 2 | 2023 | 1946 | 0.280 |
Why?
|
Eosinophils | 1 | 2011 | 952 | 0.270 |
Why?
|
Skin Neoplasms | 4 | 2023 | 5863 | 0.270 |
Why?
|
Prognosis | 22 | 2024 | 30009 | 0.260 |
Why?
|
Apoptosis | 4 | 2020 | 9527 | 0.260 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2010 | 663 | 0.260 |
Why?
|
Sulfonamides | 5 | 2022 | 1982 | 0.260 |
Why?
|
Central Nervous System Neoplasms | 1 | 2014 | 928 | 0.260 |
Why?
|
Pyrroles | 3 | 2018 | 1124 | 0.250 |
Why?
|
Soft Tissue Neoplasms | 1 | 2014 | 1164 | 0.250 |
Why?
|
Transplantation, Homologous | 8 | 2019 | 4834 | 0.250 |
Why?
|
Vincristine | 2 | 2022 | 1040 | 0.250 |
Why?
|
Treatment Outcome | 20 | 2024 | 65379 | 0.240 |
Why?
|
Survival Analysis | 10 | 2020 | 10099 | 0.240 |
Why?
|
Splenomegaly | 2 | 2016 | 192 | 0.240 |
Why?
|
Insurance, Health | 1 | 2017 | 2517 | 0.240 |
Why?
|
Skin Diseases | 1 | 2013 | 1085 | 0.230 |
Why?
|
Mast Cells | 1 | 2011 | 1406 | 0.230 |
Why?
|
Leukemia | 3 | 2023 | 1519 | 0.230 |
Why?
|
Acute Disease | 7 | 2023 | 7243 | 0.220 |
Why?
|
Quality of Life | 9 | 2023 | 13490 | 0.220 |
Why?
|
Young Adult | 23 | 2024 | 60066 | 0.220 |
Why?
|
Neoplasms | 5 | 2023 | 22371 | 0.210 |
Why?
|
Clinical Trials as Topic | 7 | 2024 | 8052 | 0.210 |
Why?
|
Mitoxantrone | 2 | 2019 | 148 | 0.200 |
Why?
|
Retrospective Studies | 25 | 2021 | 81760 | 0.200 |
Why?
|
Proportional Hazards Models | 6 | 2022 | 12543 | 0.200 |
Why?
|
Benzodiazepines | 2 | 2018 | 1138 | 0.190 |
Why?
|
Thrombocytopenia | 2 | 2023 | 1179 | 0.190 |
Why?
|
Incidence | 5 | 2023 | 21538 | 0.190 |
Why?
|
Cell Cycle | 1 | 2009 | 2934 | 0.180 |
Why?
|
Primary Myelofibrosis | 1 | 2023 | 209 | 0.180 |
Why?
|
Etoposide | 2 | 2019 | 639 | 0.180 |
Why?
|
Fatal Outcome | 2 | 2018 | 1836 | 0.180 |
Why?
|
Drug Evaluation | 2 | 2020 | 642 | 0.180 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2012 | 1642 | 0.180 |
Why?
|
Glioma | 1 | 2016 | 3503 | 0.180 |
Why?
|
Medical Oncology | 6 | 2024 | 2346 | 0.180 |
Why?
|
Bone Neoplasms | 1 | 2013 | 2565 | 0.180 |
Why?
|
Ohio | 1 | 2021 | 321 | 0.170 |
Why?
|
Benzothiazoles | 2 | 2011 | 248 | 0.170 |
Why?
|
Boron Compounds | 1 | 2022 | 196 | 0.170 |
Why?
|
Blast Crisis | 1 | 2020 | 102 | 0.170 |
Why?
|
Age Factors | 7 | 2021 | 18415 | 0.160 |
Why?
|
Follow-Up Studies | 10 | 2019 | 39354 | 0.160 |
Why?
|
Genes, sry | 1 | 2018 | 4 | 0.160 |
Why?
|
Furans | 2 | 2011 | 202 | 0.160 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2014 | 4058 | 0.150 |
Why?
|
Medicare Part C | 1 | 2023 | 332 | 0.150 |
Why?
|
Neoplasm, Residual | 3 | 2018 | 1015 | 0.150 |
Why?
|
Cytogenetic Analysis | 2 | 2019 | 271 | 0.150 |
Why?
|
Fatigue | 2 | 2016 | 1557 | 0.150 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2022 | 878 | 0.150 |
Why?
|
Tretinoin | 1 | 2021 | 525 | 0.150 |
Why?
|
Cyclopentanes | 1 | 2018 | 87 | 0.150 |
Why?
|
Drug Administration Schedule | 3 | 2021 | 4861 | 0.150 |
Why?
|
Demography | 1 | 2022 | 1641 | 0.150 |
Why?
|
Respiration Disorders | 1 | 2021 | 364 | 0.150 |
Why?
|
Pleural Effusion | 1 | 2021 | 344 | 0.150 |
Why?
|
Isoenzymes | 2 | 2020 | 1688 | 0.150 |
Why?
|
Adolescent | 15 | 2024 | 89169 | 0.140 |
Why?
|
Histocompatibility | 1 | 2018 | 321 | 0.140 |
Why?
|
Cell Differentiation | 5 | 2024 | 11677 | 0.140 |
Why?
|
Antigens, CD19 | 1 | 2020 | 446 | 0.140 |
Why?
|
Combined Modality Therapy | 3 | 2018 | 8542 | 0.140 |
Why?
|
Mutant Proteins | 1 | 2018 | 488 | 0.140 |
Why?
|
Databases, Factual | 4 | 2018 | 8080 | 0.140 |
Why?
|
Terminal Care | 2 | 2021 | 1770 | 0.140 |
Why?
|
Immune Evasion | 1 | 2020 | 375 | 0.130 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2024 | 10763 | 0.130 |
Why?
|
Adenocarcinoma | 1 | 2014 | 6395 | 0.130 |
Why?
|
Gene Frequency | 3 | 2018 | 3623 | 0.130 |
Why?
|
Asparaginase | 1 | 2017 | 240 | 0.130 |
Why?
|
Multivariate Analysis | 5 | 2020 | 12077 | 0.130 |
Why?
|
Pyrazines | 2 | 2019 | 1205 | 0.130 |
Why?
|
Sweating | 1 | 2016 | 155 | 0.130 |
Why?
|
Lung | 1 | 2014 | 10101 | 0.130 |
Why?
|
Transplantation Chimera | 1 | 2018 | 594 | 0.130 |
Why?
|
Marital Status | 1 | 2017 | 426 | 0.130 |
Why?
|
DNA Methylation | 3 | 2020 | 4428 | 0.120 |
Why?
|
Anemia, Macrocytic | 1 | 2015 | 53 | 0.120 |
Why?
|
Body Mass Index | 1 | 2013 | 13053 | 0.120 |
Why?
|
Leukemia, Myeloid, Accelerated Phase | 1 | 2014 | 7 | 0.120 |
Why?
|
Dendritic Cells | 3 | 2023 | 2747 | 0.120 |
Why?
|
Antifungal Agents | 1 | 2020 | 761 | 0.120 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2023 | 2956 | 0.120 |
Why?
|
Biochemical Phenomena | 1 | 2015 | 59 | 0.120 |
Why?
|
Diagnosis, Differential | 3 | 2016 | 13013 | 0.120 |
Why?
|
Hypotension | 1 | 2021 | 888 | 0.120 |
Why?
|
Cell Division | 1 | 2022 | 4477 | 0.120 |
Why?
|
Hospice Care | 1 | 2021 | 678 | 0.120 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 1 | 2014 | 37 | 0.120 |
Why?
|
DNA Mutational Analysis | 4 | 2022 | 4120 | 0.120 |
Why?
|
Glutamine | 1 | 2017 | 577 | 0.120 |
Why?
|
Leukocyte Transfusion | 1 | 2014 | 56 | 0.120 |
Why?
|
Transplantation Conditioning | 2 | 2018 | 1601 | 0.110 |
Why?
|
Hematinics | 1 | 2017 | 282 | 0.110 |
Why?
|
Glutaminase | 1 | 2013 | 31 | 0.110 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 2014 | 229 | 0.110 |
Why?
|
Elafin | 1 | 2013 | 30 | 0.110 |
Why?
|
United States | 9 | 2023 | 73039 | 0.110 |
Why?
|
Thiadiazoles | 1 | 2013 | 63 | 0.110 |
Why?
|
Antibodies, Bispecific | 1 | 2016 | 204 | 0.110 |
Why?
|
Fever | 1 | 2021 | 1614 | 0.110 |
Why?
|
Anthracyclines | 2 | 2019 | 286 | 0.100 |
Why?
|
Granulocyte Precursor Cells | 1 | 2012 | 49 | 0.100 |
Why?
|
Sulfides | 1 | 2013 | 171 | 0.100 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2021 | 4640 | 0.100 |
Why?
|
Nuclear Proteins | 3 | 2018 | 5804 | 0.100 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2016 | 614 | 0.100 |
Why?
|
Retreatment | 1 | 2014 | 598 | 0.100 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 1 | 2014 | 288 | 0.100 |
Why?
|
Cladribine | 1 | 2012 | 34 | 0.100 |
Why?
|
Practice Guidelines as Topic | 1 | 2010 | 7454 | 0.100 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2014 | 452 | 0.100 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2013 | 658 | 0.100 |
Why?
|
Hematopoietic Stem Cells | 2 | 2016 | 3409 | 0.100 |
Why?
|
Animals | 10 | 2023 | 169285 | 0.100 |
Why?
|
Antibiotic Prophylaxis | 1 | 2017 | 640 | 0.100 |
Why?
|
Boston | 3 | 2021 | 9374 | 0.100 |
Why?
|
Syndrome | 1 | 2018 | 3273 | 0.100 |
Why?
|
Human T-lymphotropic virus 1 | 1 | 2012 | 143 | 0.100 |
Why?
|
Adrenal Cortex Hormones | 1 | 2021 | 1886 | 0.100 |
Why?
|
Mutagenesis, Insertional | 1 | 2014 | 661 | 0.100 |
Why?
|
Venous Thrombosis | 1 | 2021 | 1321 | 0.100 |
Why?
|
Biopsy | 2 | 2014 | 6792 | 0.100 |
Why?
|
Medically Uninsured | 1 | 2017 | 840 | 0.090 |
Why?
|
Dioxygenases | 1 | 2014 | 353 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 4 | 2017 | 6525 | 0.090 |
Why?
|
Affect | 1 | 2019 | 1495 | 0.090 |
Why?
|
Colony-Forming Units Assay | 1 | 2011 | 351 | 0.090 |
Why?
|
Vidarabine | 1 | 2012 | 337 | 0.090 |
Why?
|
Adaptation, Psychological | 4 | 2022 | 2663 | 0.090 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2013 | 355 | 0.090 |
Why?
|
Cyclooxygenase 2 | 1 | 2013 | 598 | 0.090 |
Why?
|
Cough | 1 | 2014 | 598 | 0.090 |
Why?
|
Staurosporine | 1 | 2011 | 241 | 0.090 |
Why?
|
Immunotherapy, Adoptive | 1 | 2020 | 1512 | 0.090 |
Why?
|
Needs Assessment | 1 | 2016 | 1141 | 0.090 |
Why?
|
Hospitalization | 3 | 2021 | 10840 | 0.080 |
Why?
|
Risk Factors | 10 | 2021 | 74944 | 0.080 |
Why?
|
Leukapheresis | 2 | 2020 | 150 | 0.080 |
Why?
|
Anxiety | 5 | 2023 | 4672 | 0.080 |
Why?
|
Stomach | 1 | 2014 | 701 | 0.080 |
Why?
|
Educational Status | 1 | 2017 | 2515 | 0.080 |
Why?
|
Hypercalcemia | 1 | 2012 | 424 | 0.080 |
Why?
|
Cell Survival | 3 | 2020 | 5789 | 0.080 |
Why?
|
Radiography, Abdominal | 1 | 2012 | 541 | 0.080 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 5432 | 0.080 |
Why?
|
Immunoprecipitation | 1 | 2011 | 874 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2021 | 3604 | 0.080 |
Why?
|
Patient Admission | 1 | 2016 | 1365 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1942 | 0.080 |
Why?
|
Critical Care | 1 | 2021 | 2715 | 0.080 |
Why?
|
Odds Ratio | 3 | 2020 | 9669 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 2 | 2021 | 18065 | 0.080 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2013 | 778 | 0.080 |
Why?
|
Income | 1 | 2017 | 1878 | 0.080 |
Why?
|
Skull | 1 | 2013 | 829 | 0.080 |
Why?
|
Clone Cells | 1 | 2011 | 1670 | 0.070 |
Why?
|
Social Class | 1 | 2017 | 2008 | 0.070 |
Why?
|
beta Catenin | 1 | 2013 | 1047 | 0.070 |
Why?
|
Massachusetts | 1 | 2021 | 8890 | 0.070 |
Why?
|
Treatment Failure | 1 | 2014 | 2661 | 0.070 |
Why?
|
Consciousness Disorders | 1 | 2012 | 445 | 0.070 |
Why?
|
Cause of Death | 2 | 2021 | 3721 | 0.070 |
Why?
|
Immunohistochemistry | 2 | 2022 | 11095 | 0.070 |
Why?
|
Recombinant Fusion Proteins | 1 | 2016 | 3740 | 0.070 |
Why?
|
Chest Pain | 1 | 2014 | 1101 | 0.070 |
Why?
|
Prednisone | 1 | 2012 | 1567 | 0.070 |
Why?
|
Prospective Studies | 5 | 2021 | 54924 | 0.070 |
Why?
|
Anemia | 1 | 2017 | 1514 | 0.070 |
Why?
|
Diarrhea | 1 | 2014 | 1320 | 0.070 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2016 | 2568 | 0.070 |
Why?
|
Drug Therapy, Combination | 2 | 2020 | 6316 | 0.070 |
Why?
|
Chromosome Aberrations | 1 | 2013 | 1778 | 0.070 |
Why?
|
Breast Neoplasms | 1 | 2014 | 21207 | 0.070 |
Why?
|
Dyspnea | 1 | 2014 | 1352 | 0.070 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2017 | 2145 | 0.070 |
Why?
|
Head | 1 | 2012 | 926 | 0.070 |
Why?
|
Cyclophosphamide | 1 | 2012 | 2227 | 0.070 |
Why?
|
Flavonoids | 1 | 2009 | 447 | 0.070 |
Why?
|
Abdominal Pain | 1 | 2012 | 1070 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 2 | 2021 | 3231 | 0.060 |
Why?
|
Intensive Care Units | 1 | 2019 | 3800 | 0.060 |
Why?
|
Genotype | 2 | 2021 | 13045 | 0.060 |
Why?
|
Random Allocation | 2 | 2021 | 2395 | 0.060 |
Why?
|
Hospital Mortality | 1 | 2019 | 5349 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 10397 | 0.060 |
Why?
|
Poverty | 1 | 2017 | 2720 | 0.060 |
Why?
|
Neoplastic Stem Cells | 1 | 2013 | 1351 | 0.060 |
Why?
|
Population Surveillance | 1 | 2015 | 2596 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9262 | 0.060 |
Why?
|
Neurodegenerative Diseases | 1 | 2014 | 1094 | 0.060 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2022 | 2521 | 0.060 |
Why?
|
Echocardiography | 1 | 2017 | 5047 | 0.060 |
Why?
|
Amino Acid Transport System ASC | 1 | 2024 | 16 | 0.060 |
Why?
|
Ventricular Function, Left | 1 | 2017 | 3941 | 0.060 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2013 | 2062 | 0.060 |
Why?
|
Insurance, Medigap | 1 | 2023 | 20 | 0.060 |
Why?
|
Signal Transduction | 3 | 2013 | 23648 | 0.060 |
Why?
|
Neutrophils | 1 | 2016 | 3786 | 0.060 |
Why?
|
Blotting, Western | 1 | 2011 | 5028 | 0.060 |
Why?
|
Tumor Cells, Cultured | 1 | 2011 | 6124 | 0.050 |
Why?
|
Medicaid | 1 | 2017 | 2840 | 0.050 |
Why?
|
Tablets | 1 | 2024 | 149 | 0.050 |
Why?
|
Radiography | 1 | 2014 | 6986 | 0.050 |
Why?
|
Stroke Volume | 1 | 2017 | 5622 | 0.050 |
Why?
|
Diamines | 1 | 2023 | 60 | 0.050 |
Why?
|
Interleukin-3 Receptor alpha Subunit | 1 | 2023 | 36 | 0.050 |
Why?
|
Lung Neoplasms | 1 | 2008 | 13586 | 0.050 |
Why?
|
Indoles | 1 | 2011 | 1836 | 0.050 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2024 | 303 | 0.050 |
Why?
|
Leukocyte Count | 2 | 2020 | 1609 | 0.050 |
Why?
|
Disease Management | 3 | 2020 | 2535 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2011 | 2459 | 0.050 |
Why?
|
Blood Transfusion | 2 | 2020 | 1309 | 0.050 |
Why?
|
Colitis, Ulcerative | 1 | 2014 | 1926 | 0.050 |
Why?
|
Depression | 4 | 2023 | 8230 | 0.050 |
Why?
|
Time Factors | 4 | 2021 | 40220 | 0.050 |
Why?
|
Cardiomyopathies | 1 | 2014 | 2057 | 0.050 |
Why?
|
Glioblastoma | 1 | 2016 | 3464 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4528 | 0.050 |
Why?
|
Nuclear Pore Complex Proteins | 1 | 2022 | 165 | 0.050 |
Why?
|
Heart Diseases | 1 | 2014 | 2819 | 0.050 |
Why?
|
Administration, Oral | 2 | 2019 | 4034 | 0.050 |
Why?
|
Quinuclidines | 1 | 2020 | 27 | 0.050 |
Why?
|
Genome, Human | 1 | 2014 | 4446 | 0.040 |
Why?
|
Ultrasonography | 1 | 2014 | 6004 | 0.040 |
Why?
|
Anthracenes | 1 | 2020 | 83 | 0.040 |
Why?
|
Palliative Care | 3 | 2021 | 3643 | 0.040 |
Why?
|
Phosphorylation | 1 | 2011 | 8316 | 0.040 |
Why?
|
U937 Cells | 1 | 2020 | 260 | 0.040 |
Why?
|
Cohort Studies | 5 | 2021 | 41753 | 0.040 |
Why?
|
Hyperbilirubinemia | 1 | 2020 | 74 | 0.040 |
Why?
|
Skin | 1 | 2013 | 4505 | 0.040 |
Why?
|
Logistic Models | 3 | 2020 | 13290 | 0.040 |
Why?
|
North America | 1 | 2023 | 1289 | 0.040 |
Why?
|
Disease Progression | 2 | 2013 | 13668 | 0.040 |
Why?
|
Standard of Care | 1 | 2023 | 568 | 0.040 |
Why?
|
Registries | 1 | 2014 | 8375 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 860 | 0.040 |
Why?
|
Histocompatibility Testing | 1 | 2019 | 716 | 0.040 |
Why?
|
Prednisolone | 1 | 2018 | 326 | 0.040 |
Why?
|
Cell Proliferation | 1 | 2013 | 10478 | 0.040 |
Why?
|
Death | 1 | 2021 | 683 | 0.030 |
Why?
|
Off-Label Use | 1 | 2018 | 185 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2021 | 1864 | 0.030 |
Why?
|
Antilymphocyte Serum | 1 | 2018 | 492 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2014 | 9617 | 0.030 |
Why?
|
Cytokines | 1 | 2011 | 7452 | 0.030 |
Why?
|
Molecular Structure | 1 | 2020 | 1884 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2016 | 9118 | 0.030 |
Why?
|
Biphenyl Compounds | 1 | 2020 | 1026 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2013 | 5891 | 0.030 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5367 | 0.030 |
Why?
|
Cell Count | 1 | 2018 | 1832 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1737 | 0.030 |
Why?
|
Receptors, Immunologic | 1 | 2020 | 1418 | 0.030 |
Why?
|
HLA Antigens | 1 | 2019 | 1334 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1793 | 0.030 |
Why?
|
Coronary Artery Disease | 1 | 2013 | 6568 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 15662 | 0.030 |
Why?
|
Risk Assessment | 3 | 2019 | 24318 | 0.030 |
Why?
|
Liver | 2 | 2019 | 7578 | 0.030 |
Why?
|
Neoplasm Staging | 1 | 2008 | 11244 | 0.030 |
Why?
|
Bone Marrow Examination | 1 | 2013 | 154 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2008 | 15949 | 0.030 |
Why?
|
Benchmarking | 1 | 2019 | 1057 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2019 | 14783 | 0.020 |
Why?
|
Switzerland | 1 | 2013 | 323 | 0.020 |
Why?
|
Hemoglobins | 1 | 2018 | 1531 | 0.020 |
Why?
|
Perception | 1 | 2018 | 1209 | 0.020 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2013 | 430 | 0.020 |
Why?
|
K562 Cells | 1 | 2013 | 644 | 0.020 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2013 | 361 | 0.020 |
Why?
|
History, 21st Century | 1 | 2017 | 1573 | 0.020 |
Why?
|
Karyotyping | 1 | 2013 | 1177 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2020 | 17142 | 0.020 |
Why?
|
Mortality | 1 | 2021 | 2911 | 0.020 |
Why?
|
Stem Cell Transplantation | 1 | 2018 | 1599 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2020 | 3713 | 0.020 |
Why?
|
Pilot Projects | 1 | 2023 | 8741 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2013 | 2014 | 0.020 |
Why?
|
Pyrazoles | 1 | 2020 | 2028 | 0.020 |
Why?
|
Boronic Acids | 1 | 2013 | 915 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 20762 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2013 | 1169 | 0.020 |
Why?
|
Comorbidity | 2 | 2017 | 10590 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1397 | 0.020 |
Why?
|
Protein Binding | 1 | 2020 | 9343 | 0.020 |
Why?
|
Thalidomide | 1 | 2013 | 886 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2017 | 2057 | 0.020 |
Why?
|
Mice, Nude | 1 | 2014 | 3623 | 0.020 |
Why?
|
Forecasting | 1 | 2016 | 2945 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3436 | 0.020 |
Why?
|
Genetic Variation | 1 | 2021 | 6610 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2017 | 3573 | 0.020 |
Why?
|
Myocardial Infarction | 1 | 2006 | 11519 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2014 | 2433 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3269 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 26379 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2014 | 6231 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2013 | 2393 | 0.010 |
Why?
|
Decision Making | 1 | 2018 | 3953 | 0.010 |
Why?
|
Alleles | 1 | 2015 | 6894 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 8648 | 0.010 |
Why?
|
Monocytes | 1 | 2013 | 2605 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2015 | 3670 | 0.010 |
Why?
|
Child | 2 | 2023 | 80917 | 0.010 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2014 | 3610 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5536 | 0.010 |
Why?
|
Genetic Testing | 1 | 2015 | 3591 | 0.010 |
Why?
|
Zebrafish | 1 | 2013 | 3035 | 0.010 |
Why?
|
Heart | 1 | 2014 | 4446 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2013 | 9561 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2020 | 16044 | 0.010 |
Why?
|
Cell Line | 1 | 2014 | 15602 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9540 | 0.010 |
Why?
|
Mice | 2 | 2014 | 82049 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15453 | 0.010 |
Why?
|
Prevalence | 1 | 2006 | 15869 | 0.010 |
Why?
|